Key facts
- This page summarizes Paul Burton's Form 4 filing for Moderna, Inc. (MRNA).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 08 Nov 2022, 15:08.
Paul Burton - 04 Nov 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- MRNA
- Reported as of
- 04 Nov 2022
- Net transaction value
- -$30,467
- SEC form
- 4
- Accepted by SEC
- 08 Nov 2022, 15:08:49 UTC
- Prior SEC filing
- 09 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian Sandstrom, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Paul Burton filed Form 4 for Moderna, Inc. (MRNA) on 08 Nov 2022.
Change
- Previous filing in this sequence was filed on 09 Aug 2022.
- Current net transaction value: -$30,467.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRNA
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +402
- Change %
- +54%
- Price
- $0.000000
- Shares after
- 1,146
- Date
- 04 Nov 2022
- Ownership
- Direct
- Footnotes
- F1
MRNA
transaction
Common Stock
Sale
- Transaction value
- $30,467
- Shares
- -192
- Change %
- -17%
- Price
- $158.68
- Shares after
- 954
- Date
- 07 Nov 2022
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRNA
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -402
- Change %
- -8.3%
- Price
- $0.000000
- Shares after
- 4,427
- Date
- 04 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 402
- Exercise price
- $0.000000
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Restricted stock units convert into common stock on a one-for-one basis.
Footnote F2
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Footnote F3
25% of the shares subject to this restricted stock unit award vested on August 5, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.